Joanne Blum, MD, PhD, discusses the function of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer.
Joanne Blum, MD, PhD
Articles by Joanne Blum, MD, PhD
Latest Updated Articles
Dr. Joanne Blum on the Function of Talazoparib in Locally Advanced and/or Metastatic Breast CancerPublished: December 23rd 2015 | Updated: